Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danazol low-dose - Ampio Pharmaceuticals

Drug Profile

Danazol low-dose - Ampio Pharmaceuticals

Alternative Names: Optina; Vasaloc

Latest Information Update: 06 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Oxazoles; Small molecules
  • Mechanism of Action Actin modulators; Capillary permeability modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic macular oedema

Highest Development Phases

  • Phase III Diabetic macular oedema
  • No development reported Allergic rhinitis; Diabetic nephropathies; Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 31 Dec 2016 Ampio Pharmaceuticals has patent protection for donazol low-dose for the treatment of Macular oedema or Diabetic nephropathy in USA, Australia, Europe, Hong Kong, Japan, Mexico, New Zealand, South Africa, Singapore and Canada
  • 31 Dec 2016 Ampio Pharmaceuticals has patents pending for danazol low-dose in USA, Australia, Brazil, China, Canada, Eurasia, Europe, Indonesia, Israel, Japan, Korea, Mexico, Malaysia, Philippines, Singapore and Hong Kong
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetic-nephropathies in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top